Genetically Encoded Biosensors for Drug Discovery
Live-cell monitoring of drug effect with unprecedented speed
About us
Monitoring signal transduction is a cornerstone of drug development. However, the inability to measure a drug's effects in live cells at high throughput often impedes the speed and depth of discovery. Our advanced protein engineering technology enables our clients to screen and characterize vast numbers of drug candidates with unprecedented speed. This delivery of critical, real-time data helps eliminate unviable compounds sooner, allowing for better-informed decisions and reducing the immense costs of late-stage failures.
Vision
Mission
Our mission is to accelerate the drug discovery pipeline. We partner with pharmaceutical and biotech companies to offer high-throughput screening campaigns powered by our proprietary biosensor technology. By providing unparalleled insight into a drug’s mechanism of action, we empower our clients to select the right candidates and shorten the timeline from lab to clinic.
Our Services
We evaluate compounds and biologics that activate desired JAK–STAT pathways. Our assays quantify potency (EC50), efficacy, and time-resolved signaling responses in live cells, enabling precise ranking and optimization of agonists and cytokine mimetics.
Antagonist screening
We profile small molecules and biologics that inhibit cytokine or growth factor signaling. Using selected STATeLight cell lines, we deliver high-throughput screening with rich kinetic and dynamic readouts, IC50 values, and pathway selectivity data for thousands of compounds per run.